Semaglutide Safety Concerns: Separating Fact from Fear

The biggest myth: that serious side effects are common

The most persistent misconception about Wegovy safety concerns is that the medicine is dangerous for most people who take it. The clinical trial data tells a different story. In the STEP 1 trial (68 weeks, semaglutide 2.4mg versus placebo) the overwhelming majority of side effects were gastrointestinal: nausea, loose stools, vomiting, constipation. Uncomfortable, yes. Dangerous for most people, no. The NHS semaglutide medicines page lists these clearly, and describes them as most likely after the first dose or a step up, then settling as the body adjusts.

That adjustment period is real. Some people feel quite rough for a week or two; others barely notice. A practical habit worth building early: keep a simple note on your phone logging when symptoms appear and how long they last. If something is still causing significant trouble after two weeks on the same dose, that is worth raising with your prescriber rather than pushing through alone.

Other reported effects include headache, dizziness, fatigue and injection-site reactions. Burping and acid reflux are also common enough to mention. None of these are trivial if you are experiencing them, but they are not signals of serious harm in themselves. If you want a thorough breakdown, our page covering Ozempic and semaglutide side effects goes through the full range in detail. The question of whether semaglutide is well-suited to your specific situation is exactly what a clinical consultation is designed to answer.

The side effects that genuinely need prompt attention

Distinguishing garden-variety nausea from something more serious is one of the most useful things a prescriber can explain before you start. On the topic of Wegovy side effects that warrant urgent action, there are a handful of patterns to keep clearly in mind.

Acute pancreatitis is the most important. In January 2026, the MHRA issued a formal Drug Safety Update for GLP-1 medicines, naming it as an infrequent but serious risk. The symptom to act on is severe stomach pain that does not ease and spreads towards the back, with or without vomiting. This is not the ordinary nausea of the first week. If this happens, stop the medicine and get emergency help.

Gallbladder problems are also associated with GLP-1 treatment, partly because rapid weight loss is itself a gallstone risk factor. Sudden, sharp pain under the ribs on the right side (especially after eating) should be assessed by a doctor. Severe vomiting or diarrhoea that stops you keeping fluids down can cause dehydration serious enough to affect your kidneys; drink steadily and seek help if you cannot manage it at home. Signs of an allergic reaction (swelling of the face or throat, difficulty breathing, a rapidly spreading rash) are rare but need emergency attention immediately.

People with a personal or family history of medullary thyroid carcinoma, or with MEN2 syndrome, should not use semaglutide. These are among the contraindications a prescriber checks before approving treatment, and our semaglutide safety guide covers who the medicine is and is not suitable for in more depth.

What we do and do not know about long-term use

Semaglutide has now been in clinical use for several years across both its diabetes and weight-management indications, which gives regulators and researchers a reasonable body of real-world data. Both long-term semaglutide safety data and the cardiovascular outcomes story have been studied closely: the SELECT trial showed semaglutide reduced major cardiovascular events in eligible adults with existing heart disease, a finding that has strengthened confidence in the medicine's broader profile.

What remains less certain is the picture for people who stop and restart, or who use it for many years continuously beyond the trial windows. Bone density, muscle mass preservation, and the interaction with certain long-term medications are areas where research is ongoing. NICE's recommendation for semaglutide (Wegovy) under TA875 includes a maximum two-year duration for NHS use, reflecting that the evidence base, while solid, is not yet decades-deep. If you are weighing up Wegovy specifically, our Wegovy safety page brings together what is currently known in one place. Private prescribers review this on a case-by-case basis.

The honest position is that semaglutide is not risk-free, no prescription medicine is. It carries a Black Triangle (▼) designation in the UK, meaning the MHRA requires additional monitoring. That is a routine feature of newer medicines, not a warning sign unique to this one, but it is why ongoing reporting through Yellow Card matters.

Semaglutide, contraception and other medicines: the interactions worth knowing

Because semaglutide slows gastric emptying, it can affect how quickly other medicines are absorbed. For most drugs this is clinically minor, but it is worth mentioning every medicine and supplement you take when you have your consultation. The question of whether semaglutide is safe alongside your current medicines is one a prescriber is well-placed to answer with your full medication list in front of them.

Contraception deserves a specific mention. The NHS advises using contraception throughout treatment and for a wash-out period before trying to conceive. Unlike tirzepatide, current evidence does not show that semaglutide specifically reduces the effectiveness of oral contraceptive pills, but the advice to avoid pregnancy during treatment stands firmly. Semaglutide is not recommended in pregnancy, during breastfeeding, or if conception is being planned. If your circumstances change, let your prescriber know promptly.

HRT users, people scheduled for surgery, and anyone managing a complex medical history should raise those details at the start. Our prescribers review every case individually, you can read about the clinical oversight behind our service on the clinical team page. If you have specific concerns before committing to a consultation, the contact page is there for a straightforward conversation first.